Enhanced serum DPPIV levels and/or activity have been suggested to be correlated with many metabolic diseases, such as type 2 diabetes (T2DM), obesity, cardiovascular disease, and non-alcoholic fatty liver disease (NAFLD) (Röhrborn et al., 2015; Nargis and Chakrabarti, 2018). This evidence concerns the gene DPP4 and metabolic dysfunction-associated steatotic liver disease.